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ABSTRACT 
Neurodegenerative disorders are conditions that mainly affect the brain and 
the central nervous system (CNS). Each disease type is characterised by loss of 
function which results from death of a particular region. Interestingly enough, most of 
the time disease pathology is due to loss of specific cell types in the CNS. These 
pathological conditions have both high economic costs and social implications for 
society. To treat such conditions, either the lost cells must be replaced or the cells 
surrounding the damaged tissue must be induced to undergo repair to replace the lost 
cells. The former looks more achievable whereas the latter is problematic as the CNS 
has limited ability to regenerate. For cell replacement therapies, stem cells hold much 
promise in particular bone marrow stromal stem cells (BMSSCs). 
Bone marrow stromal stem cells are phenomenal in terms of their plasticity, 
their ability to renew themselves and their availability. Just about every possible use 
of BMSSCs has been proposed from diverse fields, but little success has been 
achieved in same fields. BMSSCs have been used successfully for bone marrow 
transplants and to regenerate whole organs for cell replacement therapies. However 
current research has focused on differentiation of BMSSCs into neural tissue for cell 
replacement therapies for neurodegenerative disorders has had little success. 
The initial approach was to optimise conditions for the growth and 
differentiation of BMSSCs. Once optimal conditions were characterised, experiments 
to induce differentiation of BMSSCs only produced a_ mixture of neuronal cells. 
Ideally for cell replacement therapy, only a single type of cell lost in the disease 
process needs to be replaced. 
Pax7 is a key transcription factor that drives neural differentiation and 
migration of neural cells during development. It is also thought to determine neural 
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differentiation in the tectum, where it specifically drives the fate of precursor cells 
towards a neural lineage. Upregulation of the transcription factor Pax7 in stem cells 
may induce these stem cells to differentiate towards neural differentiation. Since Pax7 
specifies neural cell fate and not any other cell type in the CNS, transfected cells 
should differentiate into neurons similar to those found in the tectum. It is 
hypothesised that transfecting stem cells with Pax7 would create a novel method of 
differentiating stem cells into a homogeneous population of neurons. The 
differentiated cells could then be used as cellular material for cell replacement 
therapies. 
In this project a variety of stem cells, P19 cells, NIH3T3 cells and BMSSCs 
were transfected with Pax7 and assessed for neural differentiation. P19 and NIH3T3 
transfected cells clearly showed differentiation along a neurogenic lineage, 
specifically towards the neurons of midbrain. Sadly, the BMSSCs did not survive the 
transfection process and further optimisation of conditions is required to achieve 
neural differentiation of BMSSCs. 
Key words: bone marrow stromal stem cells, differentiation and cell replacement 
therapy. 
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CHAPTER! 
INTRODUCTION 
1 
NEURAL INDUCTION AND DIFFERENTIATION OF STEM 
CELLS USING THE DEVELOPMENTAL GENE PAX7 
1.1 Hypothesis 
Pax7 induces stem cells to differentiate into a homogeneous population of neurons 
in vitro. 
1.2 Aims 
1.2.1 To stably transfect P19, NIH3T3 and Bone Marrow Stromal Stem 
Cells (BMSSCs) with a full length Pax7 eDNA transcript (Pax7d). 
1.2.2 To analyse neuronal differentiation of Pax7+ stem cells. 
1.2.3 To compare neural differentiation of three different Pax7+ cell lines 
(P19, NIH3T3 and BMSSC). 
1.3 Background 
Most neurodegenerative disorders are due to loss of a specific neural cell type 
in the central nervous system (CNS). Attempts to repair the damaged CNS have 
seen the development of cell replacement therapies. These therapies attempt to use 
embryonic stem cells or neural stem cells to replace neurons lost in injury or 
neurodegenerative disorders (Snyder and Olanow, 2005). However current cell 
replacement therapies utilise embryonic or foetal neural stem cells which are 
undifferentiated and are not fully characterised. Recently a lot of effort has been 
made to differentiate neural and embryonic stem cells in vitro which can then be 
utilised in cell replacement therapies. While these cells appear promising, there 
are limitations due to the source of the cells, cell plasticity, tissue compatibility 
and ethical implications. In an attempt to overcome these problems, an alternative 
source of cells is being developed, namely Bone Marrow Stromal Stem Cells 
(BMSSCs) that can be derived from the patients own bone marrow (Holden and 
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Vogel, 2002; Moore and Quesenberry, 2003). BMSSCs are easily accessible, have 
the ability to differentiate into various cell types, are tissue compatible and have 
few ethical considerations. Recent studies have shown that it is possible to 
differentiate BMSSCs into neurons (Sanchez-Ramos et al., 2000; Woodbury et al., 
2000) but the differentiated stem cells are a mixture of different neuronal cell 
types (Azizi et al., 1998; Sanchez-Ramos et al., 2000; Woodbury et al., 2000). It is 
anticipated that in many cell replacement scenarios, it will be important to achieve 
a homogeneous population of the specific neuron cell type lost to disease or injury 
so that the function of the CNS can be restored. 
Recently our laboratory has demonstrated that Pax7 transfected into the P19 
stem cell line was able to induce more than 95% neural differentiation (Thomas et 
al., 2004; Ziman et al., 2001). Moreover the differentiated cells were of one 
specific neuron cell type when characterised by specific neural markers (Thomas 
et al., 2004). Pax7 encodes a transcription factor that is crucial for midbrain neural 
specification during development. Therefore Pax7 may successfully induce stem 
cell differentiation along a neurogenic lineage in vitro. 
1.4 Sig11iticance 
In this project we stably transfected various stem cells with the gene encoding 
the transcription factor Pax7, and assessed differentiation of stem cells into a 
homogenous population of midbrain specific neurons., A variety of stem cells were 
transfected and the transfected stem cells were fully characterised using general 
neuronal markers as well as specific markers for midbrain neurons. This study 
also address the issue of achieving a homogeneous population of neurons derived 
from BMSSCs which other studies have failed to achieve. The outcome includes 
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the differentiation of stem cells into a homogeneous population of neurons that are 
specific to the midbrain. These experiments also provide the first step towards 
achieving a population in vitro differentiated cells that can be used for cell 
replacement therapies for neurodegenerative disorders and brain injuries 
associated with the midbrain. 
4 
CHAPTER2 
BACKGROUND TO THE STUDY 
5 
2.1 Neurodegenerative disorders 
2.1.1 The problem 
Neurodegenerative disorders are variable in their aetiology (Table 2.1) and often 
the causes are not clearly established. It is thought that both genetic and 
environmental factors contribute towards the outcome of the disease (Bertram and 
Tanzi, 2005). A common characteristic of many neurodegenerative disorders is the 
partial loss of neuronal function during disease onset followed often by neuronal 
death and complete functional loss in the final stages of the disease. Interestingly, 
most neurodegenerative disorders are characterised by loss of a single neural cell type 
in the CNS. For example Parkinson's disease (PD), which is of particular interest to 
this project, results from the loss of neurons of the midbrain. PD is characterised by 
the specific loss of dopaminergic neurons in the midbrain, substantia nigra which 
controls motor function. The onset of PD is clinically characterised by partial tremors 
of the hands, arms, legs and jaws. There is also stiffness of limbs and postural 
instability (Schapira, 1999). As the disease progresses more dopaminergic neurons are 
lost and the clinical symptoms become more pronounced and drug dependency 
increases (Schapira, 1999). 
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Table2.1 Summary of neurodegenerative disorders that result from the loss of a single 
neuronal type in the CNS and the characteristics of replacement cells (Barker et al., 
2003). 
Disorder Cause of neurodegenerative Target replacement cells 
disorder 
Parkinson's disease Loss of dopaminergic neurons Nigrostriatal dopamine 
neurons 
Multiple sclerosis Oligodendrocyte in CNS CNS oligodendrocyte 
Schwann cells in PNS Schwann cells in PNS 
Amyotrophic Loss of alpha motor neurons Replacement of alpha neurons 
lateral sclerosis 
Huntington's Loss of neurons in basal Replacement of basal ganglia 
disease ganglia and cerebral cortex and cerebral cortex specific 
neurons 
Alzheimer's Deposition of amyloid causing Diffused neuronal replacement 
disease death of neuronal tissue 
Frontotemporal Loss of neurons in frontal and Replacement of frontal and 
dementia temporal lobes ofthe brain temporal lobe neurons 
A second important characteristic of many neurodegenerative disorders is the 
accumulation of protein in the neural tissue which results in cell death (Bilen and 
Bonini, 2005). Although the accumulation of protein in PD is not well characterised, 
in other neurodegenerative diseases, such as Alzheimer's disease, the disease 
symptoms are due to the accumulation of beta amyloid in the neural tissue (Verdile et 
al., 2004). Other form of brain disorders such as damage due to physical or chemical 
induced injury can affect specific brain regions. Damaged neurons do not self 
regenerate, so the lost neurons need to be replaced to restore the function of the 
particular brain region. 
2.1.2 Current treatment 
Most of the current treatments for neurodegenerative disorders are aimed at 
relieving the symptoms rather than repairing the damaged tissue and curing the 
disease (Armstrong and Barker, 2001). For example during the onset of PD, the 
symptoms are mild and the base line treatment is dopamine-replacement. Levodopa is 
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particularly effective during early stages, however as the disease progresses, 
dopamine replacement does not provide any therapeutic benefits (Schapira, 1999). 
Neurodegenerative disorders are more common in elderly patients and there 
are serious complications associated with polypharmacy in elderly patients. Long 
term over dependency on drugs results in less therapeutical benefits and more side 
effects. For these and other reasons, most research is now aimed at stem cell 
replacement therapies. 
Two definitive ways to treat neurodegenerative disorders are: 
1. Stop or reduce the protein accumulation that results in cell death or, 
2. Replace the cells that have been lost. 
Replacing the lost neural cells seems to be a more feasible option, as cell death has 
already occurred when the disease is diagnosed. 
2.1.3 Cell replacement therapy 
Cell replacement therapy involves transplanting embryonic stem cells or adult 
stem cells at the site of injury to facilitate regeneration of the damaged tissue, and has 
generated much interest as a means of treating neurodegenerative disorders. For 
successful transplant therapy, the lost cells should have modulatory action that does 
not require complex and precise patterns of connectivity (Bjorklund and Lindvall, 
2000). Cell replacement therapy is therefore a feasible solution for neurodegenerative 
disorders that result from loss of a single type of neuron in the CNS, such as PD 
(Barker et al., 2003). 
There are different approaches towards treating neurodegenerative disorders using 
cell replacement therapies. The first approach is to stimulate already existing neural 
stem cells in the CNS to proliferate and differentiate. This treatment is non-invasive 
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and overcomes the need for immunosuppression (Falk and Frisen, 2005). The second 
approach, that of neurodegenerative cell replacement therapies was initially trialled 
using undifferentiated stem cells transplanted into the damaged CNS. It was assumed 
that the undifferentiated transplanted cells would differentiate into appropriate neural 
types depending on the micro-environment of the CNS. The studies by Azizi and 
colleagues (1998) clearly demonstrated that rat mesenchymal stem cells, isolated from 
bone marrow and infused into the rat brain, successfully engrafted, migrated and 
survived (Azizi et al., 1998), albeit in very low numbers. However very few cells 
differentiated into neurons. 
A more recent approach has been to differentiate cells in vitro and then 
transplant them into the CNS to restore the functional deficiencies caused by 
neurodegenerative disorders. Through those approaches, a variety of neurological 
disorders can be treated but the most progress has been made in treating PD. 
Promising but variable results have also been obtained by transplanting 
aborted foetal tissue from the embryonic midbrain (Bjorklund and Lindvall, 2000). 
However there have been a number of setbacks with this approach: several foetuses 
are required to obtain sufficient cells, plus there are ethical concerns over the use of 
foetal tissue (Falk and Frisen, 2005). From the results of their experiment, though it 
appears that transplanting undifferentiated neuroblast to replace those that have 
degenerated in PD is a feasible approach to restore functional integrity of the 
nigrostriatal dopamine system, for patients that do not ~espond well to medical and 
pharmacological therapy (Olanow et al., 1996). 
Several studies have now been performed using embryonic stem cells, foetal 
neural stem cells as well as adult stem cells in animal models. There is great support 
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from these studies for stem cell therapies for neurodegenerative disorders especially 
PD (Kim et al., 2002; Studer, 1998) 
2.1.4 Stem cells from adult tissue 
In the mid 19th century, Cohnheim suggested that all adult stem cells reside in the 
bloodstream (Cohnheim, 1867). The hypothesis has been an issue of immense 
discussion and research since then. Recent observations have shown that small, stem-
like cells with considerable plasticity are found in a variety of adult tissues including 
muscles, fat, liver, synovial membrane and the brain (Ferrari et al., 1998; Mezey, 
2000; Petersen et al., 1999). Those cells self renew and also differentiate during tissue 
repair. This has validated Cohnheim's hypothesis. It is clear that stem cells found in 
most tissues are replenished to a small extent by stem cells found in the marrow 
(Prockop et al., 2003). 
Unlike other cells in the body, adult stem cells are characterised by two distinct 
properties: self renewal and the ability to differentiate into mature cells (McKay, 
1997; Weissman, 2000). When a stem cell divides, it undergoes asymmetric cell 
division resulting in one stem cell and one differentiated mature cell (Majka et al., 
2005), thus reserve populations of stem cells are maintained for further cell division. 
Several types of stem cells exist; totipotent stem cells from the zygote, from which 
both embryo and placenta are produced; pluripotent stem cells which give rise to only 
the embryo, and multipotent stem cells which give ri~e to the three genn layers: 
endoderm, mesoderm and ectodenn. Finally stem cells within adult tissues are 
generally committed stem cells which give rise to cells of a particular tissue (Lemoli 
et al., 2005). From one cell at fertilisation to billions of cells in an adult, cells undergo 
continuous differentiation and replacement. But not all cells in the body differentiate; 
10 
some remain as undifferentiated primitive precursor cells and upon damage to the 
tissue, help in the regeneration of the tissue (Johansson et al., 1999; Lemoli et al., 
2005). 
The major cell types in the CNS are neurons, astrocytes and oligodendrocytes. 
They are derived during development from neuronal stem cells formed in the 
regenerative zone along the entire neuraxis (Gage, 2000; McKay, 1997). Since the 
previous decade, the adult mammalian neural system was considered to be non-
renewable tissue (McKay, 1997), but this principle has been challenged by studies 
which have shown that neuronal progenitor cells found in the CNS are capable of cell 
division (Falk and Frisen, 2005). 
The first evidence of neural stem cells in the brain came from the in vitro 
culturing of adult brain cells. Cells were cultured in the presence of growth factors 
and a small number of cells proliferated to form neuropheres. These cells were then 
able to differentiate into neurons, astrocytes and oligodendrocyte, thus showing 
characteristic of true stem cells (Reynolds and Weiss, 1996; Richards et al., 1992). In 
addition, the observed changes in neurons in the adult brain of songbirds, important 
for the annual change of song patterns, provided further evidence of addition of 
neurons in the mature brain (Nottebohm, 2004). Newly generated neurons in the adult 
brain are derived from neural stem cells formed in the sub-ventricular zone and 
hippocampus (Gage, 2000). 
Although the adult human brain demonstrates regene_ration in specific areas, there 
is a limit to the extent to which the CNS will regenerate. It is believed that this is due 
to lack of sufficient endogenous factors to activate endogenous neural stem cells in 
sufficient amounts to repair the damaged CNS (Peterson, 2002). Recent experiments 
suggest that BMSSCs can be induced to differentiate into neural cells (Grove et al., 
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2004). Thus BMSSCs could be used for neural cell transplant therapies if BMSSCs 
could be induced to differentiate into a specific neural cell type. 
2.1.5 Limitations of cell replacement therapies 
Several studies have shown that transplanted stem cells do not necessarily 
differentiate into a required specific neural cell type. For functional benefits, 
transplanted cell should be able to integrate into the mature brain and establish 
appropriate connections (Falk and Frisen, 2005). Cell replacement therapies should 
therefore be used to replace cells that do not require complex connections and have 
relatively simple functions. The other challenge for successful cell replacement 
therapy is to control cell differentiation to produce only one specific cell type. The 
other challenge is to control proliferation once the cells are transplanted in the CNS; 
otherwise tumour formation results (Falk and Frisen, 2005). Once the differentiated 
cells have been transplanted in the CNS, they should lose their proliferative properties 
and become tissue committed cells which cannot proliferate further. 
Though the stem cell isolation methods are well established, a major setback is 
that little is known about the safety of transplanting stem cells subjected to current 
isolation methods. Generally these cells are labelled with antibodies and conjugated 
with fluorescent dye or magnetic particles and sorted using fluorescence activated cell 
sorting (F ACS) or a magnetic field. These methods tend to employ chemicals and 
dyes such as Hoechst 33342 and Rhodamin 123 (Goodel! et al., 1996; Ratajczak et al., 
1998). The effects of these dyes on the stem cells are not yet established and could 
change the primitive fate of the stem cells. This could limit the ability of stem cells to 
differentiate along a particular lineage and may be a reason why little success has 
been achieved in differentiating stem cells into homogenous populations of neurons. 
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BMSSCs can also be sorted in accordance with their property of adherence to 
plastic (Rando and Blau, 1994). BMSSCs isolated by adherence to plastic are not 
actually homogeneous but the cells become homogeneous in appearance when grown 
in culture for longer and they lose their haematopoietic properties (Ono et al., 2003). 
2.1.6 The ideal cells 
As previously discussed (1.3), a major limitation of cell replacement therapy is 
sourcing of the cells. The cells predominantly used are embryonic stem cells and 
neural stem cells. However the ideal replacement cells for successful cell replacement 
therapy should meet six conditions: 
1. Lots of cells should be available for harvesting with no risk of depletion. 
2. The cells should be compatible with indefinite expansion in vitro without 
loss of plasticity. 
3. The harvested cells should be able to differentiate into a homogeneous 
population of cells. 
4. The cells should posses plasticity or be able to undergo trans-
differentiation into specific mature neurons able to integrate into the 
mature brain upon transplantation. 
5. There should be no risk of cell rejection after transplantation. 
6. There should be no risk of cell proliferation and formation of tumours. 
BMSSCs are ideal cells that would meet all of the above criteria and overcome 
major problems that currently face cell replacement therapy. BMSSCs replenish 
themselves and can be either harvested from bone marrow or blood, thus are easier to 
access than neural stem cells and embryonic stem cells. Transgenic plasticity is a key 
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property of bone marrow stem cells; they are able to differentiate into cells that are 
phenotypically unrelated to the tissue of origin (Bianco et al., 2001). Lastly, since the 
cells are isolated from the patients own bone marrow, they do not pose a threat of cell 
rejection and thus no immunosuppression would be required to graft the cells into the 
CNS. 
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2.2 Bone marrow stromal stem cells (BMSSCs) 
2.2.1 BMSSC plasticity 
Bone marrow stromal stem cells normally contribute to the regeneration of 
mesenchymal tissue such as bone, cartilage, ligaments, tendons and muscles 
(Bruder et al., 1997; Ferrari et al., 1998; Petersen et al., 1999). Studies by 
Woodbury et al, (2000) and Sanchez-Ramos et al, (2000) have shown that rat 
bone marrow can be induced to differentiate into neurons and astrocytes in vitro 
and BMSSCs when transplanted into the damaged CNS, have the potential to 
migrate and differentiate into neuronal tissue in animal models (Sanchez-Ramos et 
al., 2000; Woodbury et al., 2000). 
Interestingly BMSSCs transplanted into the brain have a tendency to 
differentiate into neurons whereas BMSSCs transplanted into the spinal cord have 
a tendency to differentiate into astrocytes (Shihabuddin et al., 2000). This is an 
important finding as it indicates that the fate of transplanted BMSSCs is directed 
by the micro-environment of the host tissue rather than the pre-programmed fate 
of the cells themselves (Spradling et al., 2001; Watt and Hogan, 2000). 
Results from our lab suggest that Pax7 is a key micro-environmental factor in 
regionalisation and specification of neurons of the superior colliculus (or the 
tectum in lower vertebrate). Thus transfecting BMSSCs or any stem cell with 
Pax7 could create a similar micro-environment to that found in vivo and induce 
differentiation of stem cells into neurons specific to the superior colliculus. 
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2.2.2 Ethical considerations 
Embryonic stem cells, which are derived from the inner cell mass of the 
embryo, are the most totipotent cells and are capable of differentiating into any 
cell of the body. The recent controversy surrounding the procurement of 
embryonic stem cells has divided people into supporters of therapeutic cloning 
and non~supporters of therapeutic cloning. Recent legislation permits the use of 
these stem cells for therapeutic cloning. However ethical considerations remain a 
limiting factor. 
There are few, if any, such ethical considerations when harvesting BMSSCs. 
The harvesting of BMSSCs is done by withdrawing bone marrow from an adult, 
typically patients themselves. It does not involve any long term/irreversible 
procedure thus overcoming the ethical considerations associated with the use of 
embryonic stem cells. 
2.2.3 Supply and availabilitv 
The greatest advantage of BMSSCs is the fact that they are readily available in 
the blood and in the bone marrow of the adult patient. The cells can be isolated 
from blood by il'\iecting a growth factor, colony stimulating factor into the blood 
stream of the patient for five days which enhances proliferation of these cells. 
Haematopoietic stem cells are then collected through aphresis (Cutler and Autin, 
2001). 
An alternative way of harvesting BMSSC is by inserting a needle into the 
shaft of the femur or tibias and withdrawing bone marrow (Sanchez-Ramos et al., 
2000). 
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BMSSCs have also been harvested from cord blood. The first cord blood bank 
was established in 1995 in Australia, allowing patients access to stem cells from 
their own cord blood. The practise of cord blood collection is fairly recent and the 
storage procedures are complex and expensive (Australian National Pathology 
Accreditation Advisory Council., 1999). This places a major limitation on the use 
of cord blood derived stem cells relative to the more accessible BMSSCs 
harvested from bone marrow. 
2.2.4 The risk of cell rejection 
When using BMSSCs cell rejection would not arise because the cells are from 
the persons own bone marrow. According to the Bone Marrow Donor Institute of 
Australia, the only limitation associated with use of patient's own BMSSCs is 
that, if there is a genetic defect in BMSSCs since birth, then that defect would also 
be present in the BMSSCs and may affect their ability to differentiate into 
different lineages. This is an important issue to address in neurodegenerative 
disorders like familial Huntington's disease, where a gene defect cause the 
disease, and BMSSCs would have the same defect as the brain cells. BMSSCs are 
therefore not a solution where a germline mutation is present. 
In this project I will investigate the ability of the developmental gene Pax7 to 
differentiate stem cells including BMSSCs to a homogeneous population of neural 
progenitor cells for later use in cell replacement therapy to repair damage to the 
superior colliculus. Pax7 is just one of several Pax genes that could be used for 
differentiation of region specific neural cells for cell replacement therapy. 
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CHAPTER3 
ROLEOFPAX7 
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3.1 Role o(Pax genes 
Pax7 is one of several Pax genes which encode a family of transcription factors 
that are critical during development and organogenesis (Dahl et al., 1997; Mansouri et 
al., 1996a). In vertebrates, Pax genes have been conserved over millions of years 
(Jostes et al., 1990) and play very important roles in CNS, muscle, thymus, kidney 
and pancreatic development during embryogenesis. 
The expression of Pax genes in the CNS are region specific, contributing to 
regionalisation of the brain during embryogenesis (Stoykova and Gruss, 1994; Ziman 
and Kay, 1998). Pax expression is up-regulated during embryogenesis but expression 
becomes restricted to specific cells as the embryo moves towards adulthood. 
The Pax gene family has nine Pax members which encode Pax proteins that have 
a paired DNA binding domain. There are four Pax protein subgroups and their 
division into subgroups is based on their relative developmental function and degree 
of amino acid conservation (Gruss and Walther, 1992; Jostes et al., 1990; Mansouri et 
al., 1996a) refer to figure 3 .1. 
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Figure 3.1. Classification showing four subgroups of Pax genes, adapted from 
(Mansouri et al., 1996a) 
Pax proteins primarily bind to an enhancer DNA sequence in the promoter 
region of target genes and regulate expression of the . target gene, whose functional 
products control developmental pathways (Kawakami et al., 1997). The importance of 
Pax genes has been shown in mutant mice which do not survive to birth and develop 
severe deformalities (Chi and Epstein, 2002). Mutations in Pax genes cause failure of 
whole organs to develop as demonstrated by Pax3 mutant mice which exhibit neural 
20 
tube defects and multiple neural crest deficiencies (Lang et al., 2000). Moreover, 
Pax6 controls the formation of the eye in vertebrates and invertebrates. Pax6 
heterozygous mice have a small eye while homozygous mutant mice lack eyes. This 
not only proves that Pax6 is required to regulate downstream genes that form the eye 
but also indicates that the effects of Pax6 are concentration specific (Halder et al., 
1995; Quiring et al., 1994). 
Most Pax genes are expressed as alternate transcripts with variations influencing 
the efficiency and specificity of binding by the encoded protein to the target DNA 
(Vogan and Gros, 1997). Thus Pax transcription factors exhibit wide functional 
diversity and play important roles spatially and temporally to achieve the complex 
configuration of the developing embryo. 
3.2 The structure of Pax protein 
The Pax family of transcription factors have two DNA binding domains and a 
protein interaction domain; a paired domain, a homeodomain and a transactivation 
domain respectively (Ziman and Kay, 1998). The paired domain consists of six a-
helices grouped into two helix-tum-helix (HTH) motifs. The paired domain is 128 
amino acids long and is located close to theN-terminal end of the protein (Jostes et 
al., 1990) and consists of two sub domains (PAl and RED) each consisting of three a-
helices (Bopp et al., 1986). Each sub domain may bind independently to target DNA 
sequences. Moreover, the homeodomain may bind independently to DNA or at site 
adjacent to those bound by the paired domain. Refer to figures 3.2 and 3.3. 
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Figure 3.2. The structure of the Pax protein: The paired domain consists of two sub-
domains P AI and RED, each with three a-helices (Bopp et al., 1986). The conserved 
octapeptide region is located between the paired domain and the homeodomain. 
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Figure 3.3. Representation of the structure of the Pax protein with the paired domain 
(PD), octapeptide motif (OP), homeodomain (HD) and transactivation domain (TD) 
indicated. All Pax proteins have a similar structure but vary in the presence of a 
complete or partial homeodomain and/or octapeptide (Chi and Epstein, 2002). 
3.3 Expression patterns o[Pax genes 
Most of the Pax genes are expressed in the spinal cord apart from Paxl, Pax4 and 
Pax9 which are expressed in the vertebral column. 
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Table3.1: Expression of Pax genes in the CNS and their location. Adapted from 
(Underhill, 2000). 
Pax gene Location of expression 
Pax] Not expressed in CNS, expressed in developing 
vertebral colwnn 
Pax2 Midbrain-hindbrain boundary & optic stalk 
Pax3 Mesencephalon 
Pax4 Endocrine pancreas- not in the CNS 
Pax5 Midbrain-hindbrain boundary 
Pax6 Telencephalon 
Pax7 Mesencephalon 
Pax8 Midbrain-hindbrain boundary 
Pax9 Not expressed in CNS, expressed in developing 
vertebral colwnn 
Though several Pax genes are expressed in the brain during development, it is 
the restricted expression of each Pax gene that helps to establish regional boundaries 
in the brain. 
Pax-3 
Pax-2 1 Pax-8 
Pax-5 
. Pax-6 
. Pax-7 
Figure 3.4. Diagrammatic representation summarising the expression of Pax genes 
within distinct boundaries in the embryonic brain. Adapted from (Stoykova and 
Gruss, 1994) 
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3.4 The (unctiotl o(Pax7 in the CNS 
During embryogenesis, Pax7 exhibits discrete expression patterns in the CNS, as 
well as in migrating neural crest cells, and condensing somites (Jostes et al., 1990). 
Mansouri and colleagues have shown that Pax7 participates in development of neural-
crest-derived cranio-facial structures and skeletal muscle satellite cells by using 
knock-out mice (Mansouri et al., 1996b; Seale et al., 2000). Pax7 is expressed 
spatially and temporally in the CNS during early embryogenesis (day 8) through to 
postnatal development (Jostes et al., 1990) and in adults (Ziman et al., 1997). 
Alternate splicing creates alternate transcripts of Pax7, which encode isoforms 
with different structures. Each isoform is likely to bind to a different set of target 
genes (Ziman and Kay, 1998). Pax7 expresses four alternate transcripts; Pax7a, 
Pax7b, Pax7c and Pax7d, which differ by the presence or absence of a trinucleotide 
or a hexanucleotide in the paired box. This results in the respective encoded proteins 
having one or two extra amino acids included or excluded in the paired DNA binding 
domain. 
It is the inclusion or exclusion of one, two or none amino acids in the paired 
domain that determines the specificity of Pax7 isoforms for their target genes. 
Previous studies have shown that while the proportion of alternate transcripts is 
similar in brain and muscle, the more frequent combination of transcripts in brain are 
Pax7b and Pax7d while in the muscle the more common combination is Pax7a and 
Pax7c (Ziman and Kay, 1998). The transcripts exp~essed in the brain lack a 
hexanucleotide which suggests they may have a role in neurogenesis (Ziman and Kay, 
1998). Therefore in this project the Pax7d isoform was utilised as it is the most 
abundant transcript and is found predominantly in neural cells (Ziman et al., 1997). 
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3.5 Whv transfect stem cells with Pax7? 
Pax7 has been shown to participate in neurogenesis of the midbrain during 
development. Pax7 is a transcription factor that binds and regulates the expression of 
downstream target genes which are likely to be involved in neural differentiation in 
the midbrain (Thomas et al., 2006; Thomas et al., 2004; White and Ziman, 2006). 
Pax7 is expressed in the mesencephalic alar plate as early as day two during 
development and plays a role in tectum development (Jostes et al., 1990; Thomas et 
al., 2006; Thomas et al., 2004). In fact, Pax7 may be regarded as a master control 
gene for specification of the tectum as it defines the identity of the dorsal alar plate 
and ectopic expression of Pax7 in the forebrain induces formation of an ectopic tectal 
structure (Matsunaga et al., 2001; Nomura et al., 1998). 
Furthermore Pax7 is expressed in the majority of proliferative cells during early 
stages of tectal differentiation. However the expression pattern of Pax7 in later stage 
tectallaminae is not homogeneous but rather graded which suggests its importance in 
establishing tectal polarity and laminar architecture (Thomas et al., 2006; Thomas et 
al., 2004). The protein is expressed in graded concentrations, high dorsally and low 
ventrally, low rostrally and high caudally (Thomas et al., 2006). Thus Pax7 is 
expressed in distinct boundaries within the mesencephalon which helps to establish 
tectal regionalisation and polarity in the mesencephalon. It is the spatial and temporal 
expression of Pax7 that regulates development of the tectum (Thompson et al, 2006. 
In press). 
Pax7 is continuously expressed in the retino-recipient precursor laminae of the 
tectum with relative changes in Pax7 expression as differentiation occurs. Moreover 
Pax7 appears to play a role in the specification of subtypes of neurons destined to 
occupy retino-recipient precursor laminae (Thomas et al., 2006). 
25 
Our previous research has shown that stem cells transfected with Pax7 can be 
differentiated along a neurogenic lineage (Thomas et al., 2004; Ziman et al., 2001). 
Conclusive data showed that a P19 cell line stably transfected with Pax7 resulted in 
more than 95% of the cells differentiating along the neurogenic lineage (Ziman et al., 
2001). 
Moreover, three days after injury to the tectum (or superior colliculus in 
higher vertebrates), there is up regulation of Pax7 which presents a small window of 
opportunity for regeneration to occur (Thomas et al., 2006). In organisms capable of 
retinal regeneration, up regulation of Pax6 has also been observed; cells enter the cell 
cycle and repopulate the damaged retinal cells (Chi and Epstein, 2002). The results of 
these studies suggest that there are endogenous mechanisms that may assist with 
regeneration of damaged tissue (Thomas et al., 2006; Yamamoto et al., 2001). Other 
studies have shown that adult neurogenesis can be stimulated by basic Fibroblast 
Growth Factor (bFGF) and Epidermal Growth Factor (EGF) in an adult brain (Gould 
et al., 1999; Palmer et al., 1999). 
Stem cells have also been shown to differentiate into neurons through growth 
factor induction in vitro (Joannides et al., 2003). The major set back with growth 
factor induced neuronal differentiation is that differentiated cells are not well 
characterised and they are more often a mixture of different neuronal cell types. 
Given that Pax7 is the key regulator for neural differentiation in the dorsal 
midbrain and is expressed in the damaged brain three days after injury and given that 
one of the key reasons for incomplete regeneration of the CNS after damage is due to 
lack of sufficient endogenous factors (Peterson, 2002), it is possible that there is 
insufficient Pax7 to reach threshold values to cause neural proliferation, 
differentiation and repair in the adult midbrain. This study addresses the shortfall of 
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endogenous factors that drive neuronal differentiation by up regulating Pax7 in stem 
cells that can be used for cell replacement therapies to replace lost neurons. 
3.6 Implications o{usingPax7 in stem cells (or cell replacement therapv 
The potential to generate a homogeneous population of a particular type of neuron 
would enhance cell replacement therapy for diseases caused by loss of a single type of 
neuron. The use of a transcription factor that is involved in specification of neurons 
during development and which is up regulated during an injury or a disease state, to 
differentiate stem cells along a neurogenic lineage, may induce a homogeneous cell 
population for cell replacement therapies (Rossi and Cattaneo, 2002). 
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CHAPTER4 
METHODS AND MATERIALS 
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4.1 Cloning o(Pax 7d into pcDNA3.1DIV5-His-TOPO vector. 
The vector used for cloning was pcDNA3.1DN5-His-TOPO vector 
(Invitrogen) Appendix 1; it generates consistent high gene expression in mammalian 
cells compared to other commercially available vectors. 
eDNA of Pax7d transcript (Genebank accession number: NM 011039.1 
Appendix 2) cloned into pcDNA 3.1N5 HIS TOPO vector was kindly provided by 
Rob White (White and Ziman, 2006). Vectors were transfected into E. Coli, plated on 
Luria-Bertani (LB) agar plates containing 100 ~-tg/ml of ampicillin, incubated 
overnight at 3 7°C. Individual colonies from the plates were selected and grown in Sml 
of LB broth overnight at 37°C on a rocker. The pc DNA 3.1N5-HIS-TOPO vector 
map is provided in Figure 4.1. The cloned Pax7 sequence is also provided in appendix 
2. 
Figure 4.1. Graphical representation of the pcDNA 3.1N5 HIS-TOPO vector. Pax7d 
was inserted between the two TOPO sites. The vector contains a V5 epitope tag and a 
His6 tag. The vector contains a neomycin resistant gene for selection of stable 
transfected colonies in mammalian cells. 
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Plasmid DNA was isolated using a QIAprep Spin Miniprep Kit (QIAGEN) 
according to the manufacturer's instructions. E.Coli containing LB broth was 
centrifuged, supernatant removed and the pellet resuspended in 250 J.tl of buffer Pl. 
The cells were lysed in 250 J.!l alkaline solution buffer P2 for 5 minutes. The solution 
was neutralised using 350 J.tl of buffer N3, mixed gently and centrifuged at 13000rpm 
for 10 minutes. The supernatant was then applied to a silica membrane spin column, 
and the plasmid DNA was allowed to bind to the silica membrane. RNA and proteins 
were removed by centrifuging for 1 minute at 13000 rpm. The silica membrane was 
washed twice with buffer PB to remove any other impurities before DNA was eluted 
with 50 J.tl of sterile water. 
Plasmid DNA (5 J.tl) was loaded with 3 J.tl of loading buffer onto a 1% agarose 
gel containing ethidium bromide 0.1 J.tllml and electrophoresed at a constant voltage 
of 105 V for 1 hour. A 1 kb ladder was utilised for relative size comparisons. The gel 
was visualised on a Gel Doc System (BioRad) and images analysed using the 
Quantity One software program (BioRad). DNA concentrations were calculated by 
spectrophotometry at a range of dilutions. 
To confirm that Pax7 was inserted into the vector in the correct orientation, 
the Pax7d insert region was amplified by PCR using the forward primer (F4) 5'-
CACCGACTCTGGATTCGTCTCCAGCGTG-3', of which the first four bases are 
vector specific while the rest of the primer spans the 5' untranslated region of Pax7. 
The reverse primer, BGH reverse 5'-TAGAAGGCACAGTCGAGG-3', is 
complementary to the vector sequence at the 3' end of the Pax7 insert. The melting 
temperatures were calculated using a web based primer analyser (Intergrated DNA 
technologies, 
). 
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The PCR reaction was performed with QIATaq (QIAGEN, Australia) 
according to the manufacturer's specifications. Briefly, the PCR reaction contained 1x 
PCR buffer (15 mM MgC}z), 1x Q-solution, 10 !lM forward primer, 10 !lM reverse 
primer, 10 !lM dNTPs, 0.5 units of Taq polymerase per reaction and 50 ng DNA in a 
volume of 20 jll. PCR cycle conditions were: Initial denaturation for 3 minutes at 
94°C; then 30 cycles of denaturation for 1 minute at 94°C, annealing for 30 seconds at 
50°C and 2 minutes extension at 72°C followed by a final extension for 10 minutes at 
72°C. 
PCR products (5 Ill of sample with 3 Ill of loading buffer) were 
electrophoresed on a 1% agarose gel containing ethidium bromide (0.1 !ll/ml). The 
gel was run at a constant voltage of 105 V for 1 hour. The gel was visualised and the 
image was captured on a Gel Doc System (BioRad). The expected PCR product size 
was 1744 bp. 
4.2 Ethics 
This project involved use of rats to isolate bone marrow stromal stem cells. For 
this reason, ethics clearance was obtained from the Animal Ethics Committee at Edith 
Cowan University. All necessary protocols were followed so as to cause minimal pain 
to. the animals. This project also involved genetic modification to cells and therefore 
necessary notification was made to the Institutional Biosafety Committee (IBS) for 
classification of the project as an exempt dealing jn accordance with Gene 
Technology Act (2001) (IBC ref number: ED.4.2005). 
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4.3 Bone marrow extraction 
Animal ethics clearance was obtained from Edith Cowan University Animal 
Ethics Committee, (approval number 06-A3) prior to purchasing and euthanizing the 
animal. 
An 8 week old Sprague Dawley Rat (285 grams) was purchased from the Animal 
Resource Centre (Murdoch University, Perth). Upon arrival, the rat was euthanized 
with Lithabarb (Sodium Pentobarbitone) at a concentration of 15 mg/1 00 grams of 
body weight by intra-peritoneal injection (lml injection with 20G needle). Death was 
confirmed by lack of breathing and no response after pinching the toes. 
Using a surgical scalpel and a scissors, skin and muscles were cut to expose the femur 
and tibia, which were then physically detached from the body and cleaned of excess 
muscle and tendons. In a Petri dish, the ends of the femur and tibia were cut to expose 
the shaft of the bone. Bone marrow was extracted by inserting a 21 G needle and 
flushing each bone with 5 ml of a-MEM. The cell suspension was centrifuged at 
500rpm for 5 minutes. The supernatant was discarded and the cell pellet resuspended 
in 1 ml culture medium. Resuspended cells were grown in T25 culture flasks in 5 ml 
of culture medium. Culture medium comprised of a-MEM (Invitrogen), 15 % 
knockout serum (Invitrogen), and 2 mM Glutamax (Invitrogen). 
4.4 Culture BMSSCs, P19 cells and NIH3T3 cells 
BMSSCs isolated as described above, and a BMSSCs cell line (purchased 
from Tulane centre for gene therapy, New Orleans), were initially cultured in medium 
consisting of a-MEM, knockout serum and Glutamax for one week. Medium was 
changed three times a week. The BMSSCs were then cultured in growth medium for 
three weeks to obtain a pure population of BMSSCs. Growth medium consisted of 
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42% a~MEM (Invitrogen), 42% F12 (Invitrogen), 15% knockout serum (Invitrogen) 
or fetal calf serum (Invitrogen), 20 ng/ml FGF (Invitrogen), 20 ng/ml hEGF 
(Invitrogen) and 100 U/ml penicillin/streptomycin/Fungizone. 
Two cell lines were also cultured alongside the BMSSCs for experimental 
comparisons. P19 embryonic carcinoma stem cells (passage 12, ATCC, catalogue 
number CRL-1825) and NIH3T3 embryonic fibroblast (passage 10, ATCC, catalogue 
number CRL-1658) were thawed from frozen stocks and resuspended in 1 ml of 
growth medium. Resuspended cells were transferred to T25 culture flasks and grown 
in 5 ml of growth medium at 37°C in 5% carbon dioxide. The growth medium was 
changed three times a week. P 19 is an embryonic carcinoma stem cell line which has 
previously been shown to differentiate into neuronal or muscle cells. NIH3T3 is an 
embryonic mouse fibroblast stem cell line commonly used for DNA transfection 
studies. The BMSSC line is the preferred choice for cell transplant therapies as both 
P19 and NIH3T3 cell lines cause tumours, but are useful for development of in vitro 
stem cell models. 
4.5 Passaging the cells 
When cells reached 90-95% confluency, the growth medium was aspirated 
and discarded. Cells were washed with 2 ml of PBS before the addition of 3 ml of 
accutase (Chemicon) to detach cells from the flask. The flask was gently tapped to 
detach the remaining cells stuck to the flask. Accutase c~ll suspension was aspirated 
and transferred to a 15 ml falcon tube and centrifuged at 500 rpm for 5 minutes. 
Supernatant was discarded, and the cell pellet washed with 1 ml of growth medium. 
The cell pellet was then suspended in 1 ml of growth medium. The cell suspension 
(200 J..Ll) was then added to a T25 culture flask containing 5 ml of growth medium. 
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4.6 Transfection ofBMSSCs, P19 and NIH3T3 
One day prior to transfection, cells were seeded at 4-8 x 105 cells per well into 
T5 6 well tissue culture plates (Gibco) containing 2 ml of growth medium per well. 
Cells at 90-95% confluency were transfected with plasmid DNA ( 4 IJ.g) isolated as 
described in section 1.1, and mixed with 250 !J.l of Opti-MEM I reduced serum 
medium (Invitrogen). A 10 !J.l volume of lipofectamine (Invitrogen) was diluted in 
250 Ill of Opti-MEM I reduced serum medium and incubated for 5 minutes at room 
temperature. Diluted DNA was combined with diluted lipofectamine (total volume 
500 !J.l), mixed gently and incubated for 20 minutes at room temperature. Plasmid 
DNA -lipofectamine complex (500 !J.l) was added to each well containing cells plus 
medium. The contents were mixed by gently rocking the plate back and forth. Cells 
were incubated at 3 7°C in a 5% carbon dioxide incubator for 18-48 hours prior to 
testing for gene expression. After 24 hours, transfection medium was replaced with 
growth medium containing 1% gentamycin for stable transfection selection. 
4.7 SelectingPax7+ stable clones 
Cells were visualised under an inverted microscope and individual clones 
containing Pax7d, or vector alone were selected from each cell line using sterile 
swabs. Individual clones were propagated in growth medium containing 1% 
gentamycin. Prior to placing the cells in differentiation medium, expression of Pax7 
or vector was confirmed in each clone by RT-PCR and immunocytochemistry. For 
each cell line, clones expressing high levels of Pax7 or vector alone were selected for 
further experimentation. For each cell line, a total of two clones expressing Pax7 and 
two clones containg vector alone were chosen for further experiments, representing a 
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total of 4 clones (two Pax7+ and two vector alone) per cell line. Cell transfected 
vector alone did not survive the selection process so untransfected cells were utilised 
as controls. 
4.8 Differentiating the cells 
Differentiation medium consisted of 42% a-MEM, 42% F12, 15% knockout 
serum and 1 OOU/ml penicillin/streptomycin/fungizone. Before transferring cells to 
differentiation medium, the cells were analysed using R T-PCR and 
immunocytochemistry and termed Day 0. Cells were then transferred and cultured in 
differentiation medium for 7 days, after which time they were collected for RNA 
extraction and RT-PCR analysis or fixed for immunocytochemistry and termed Day 7. 
4.9 RNA extraction (or RT-PCR 
RNA from the cells was extracted using PureLink Micro-to-midi Total RNA 
purification system (Invitrogen) according to the manufactures instructions. Briefly, 
cells were pelleted by centrifugation of accutased cells at 500 rpm for 5 minutes. The 
cell pellet was washed with PBS and centrifuged at 500 rpm for 5 minutes. The cells 
were lysed with 200 f.tl of lysis buffer containing 1% P-mercaptoethanol and mixed 
gently. An equal volume of 70% RNAse free ethanol was added and mixed gently. 
Then 400 f.tl of lysate was transferred to an RNA binding spin cartridge and 
centrifuged at 12000 rpm for 15 seconds. The :flow throl!gh was discarded. A 350 J.tl 
volume of wash buffer I was added to the spin cartridge centrifuged at 12000 rpm for 
15 seconds and :flow through discarded. A further 700 J.tl of wash buffer I was added 
to the spin cartridge, centrifuged at 12000 rpm for 15 seconds and the flow through 
discarded. The spin cartridge was placed in a new RNAse free wash tube. 500 J.tl of 
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wash buffer II was added, and then the cartridge was centrifuged at 12000 rpm for 15 
seconds and the flow through discarded. A further 500 ~1 of wash buffer II was added, 
the cartridge was again centrifuged at 12000 rpm for 15 seconds and flow through 
discarded. The spin cartridge was centrifuged at 12000 rpm for a further 1 minute to 
dry the RNA binding membrane. The spin cartridge was placed in an RNAse free 
collection tube. RNAse free water (50 ~1) was placed on the RNA column for 1 
minute, and then RNA was eluted by centrifuging at 12000 rpm for 2 minutes. RNA 
was assessed by gel electrophoresis for quality and the concentration was determined 
by spectrophotometry. RNA was stored at -80°C until used in RT -PCR experiments. 
RT-PCR was used to assess Pax7 expression and neural differentiation in the 
cell line prior to and after transfection. A total of 50 ng of RNA was converted to 
eDNA using an Omniscript Reverse Transcriptase Kit (Qiagen): a 20 ~1 reaction 
contained 4 units Omniscript reverse transcriptase, 1x RT buffer (15 mM MgC12), 
dNTPs (5 mM of each dNTP) RNAse inhibitor (10 units/~1) and random hexamers as 
primers (10 ~M). The reaction was incubated at 37°C for 1 hour, and 2 ~1 of eDNA 
was utilised in eaQh downstream PCR. PCR was performed in a 20 ~1 reaction which 
contained 1x PCR buffer (15 mM MgCh), 1x Q-solution, 10 ~M forward primer, 10 
~M reverse primer, 10 ~M dNTPs, 0.5 units of Taq polymerase per reaction and 2 ~1 
eDNA. The PCR conditions for all reactions were: 94 °C for three minutes followed 
by 45 cycles comprising 94°C for 30 seconds, 52°C- 57°C for 30 seconds, 72°C for 
30 seconds and a final extension at 72°C for 10 minutes. Annealing temperatures 
ranged form 52°C- 57°C and were specific for each set of primers used in the PCR 
reactions. 
The PCR products were visualised on 1% agarose gels stained with ethidium 
bromide and analysed using the GelDoc system. All RT -PCR reaction products were 
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semi~quantified relative to GAPDH expression levels using software Quantity One 
(BioRad). Gene expression levels was analysed in duplicates for each clone of each 
stem cell type. 
For each clone transfected with Pax7, or for the cells transfected with vector 
alone, PCRs were performed on the isolated RNA with gene specific primers (Table 
4.1 ). The genes tested were Pax7, neural markers (Neurofilament, Beta Ill tubulin, 
MAP2, nestin, Engrailed 2, NCAM and Ephrin A2) or the glial marker GFAP, and 
stem cell markers (CD44, CD90 and CDJJB). The summary of gene specific primers 
used in R T -PCR reaction is shown in Table 4.1. 
Table 4.1. A summary of the genes and primers used in RT-PCR reactions to test 
neural differentiation oftransfected cells. 
Marker Forward primer 5' to 3' Reverse primer 5' to 3' 
Pax7 CACCGACTCTGGATTCGTCTCCAGCGTG ACAACCATGAGAAACACGGAGC 
GFAP TCCTGGAACAGCAAAACAAG CAGCCTCAGGTTGGTTTCATC 
Engrailed 2 TGGATGGAGTGCTCAAAGC ACCTGTTGGTCTGAAACTCAGC 
Nestin GAGTCAGATCGCTCAGATCC AAGAGAAGGATGTTGGGCTGAG 
Beta III TGGAGCGCATCAGCGTATACTAC TCTCACACTCTTTCCGCACG 
tubulin 
NCAM TACCCTCACCATCTACAACG TGTTGGACAGGACTATGAACCG 
Neurofilament CAGCAGTTGGAAAATGAACTTC GATGGCTGTGAGGGTTTCTTCC 
CD44 TGACAGGTTCCATTCACCCTCG AGGTACTGTTGAAAGCCTGGC 
CDllB ATGGGCTCAGGAAACAACTG GACCACATTCTGTCCAAAGC 
E_phrinA2 CAACGCTGACCGATACGC CATAAACCTTGAGTCGCTGGC 
GAPDH GTGAAGGTCGGTGTGAACG ATTTGATGTTAGTGGGGTCTCG 
CD90 AATCCAAGTCGGAACTCTTGGC ATCCTTGGTGGTGAAGTTGGC 
4.10 Fixing cells for lmmunocvtochemistry 
The cells grown for 0 days or 7 days in differentiation medium were cultured 
in 8 well immunocytochemistry chamber slides (Nunc) .. After 24 hours the cells were 
washed with TBS thiee times and fixed in 4% paraformaldehyde for 10 minutes. The 
cells were washed three times with Tris buffered saline (TBS) and quenched in 3% 
hydrogen peroxide for 10 minutes. The cells were again washed with TBS three 
times. Non-specific binding was blocked by incubating the cells in TBS I 0.1% 
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Product 
size 
279bp 
224bp 
273 bp 
248 bp 
246bp 
278 bp 
342bp 
276bp 
259bp 
413 bp 
233 bp 
322 bp 
Triton-X 100 I 3% normal goat serum (NUS) (Invitrogen) and 3% fetal calf serum 
(FCS) (Invitrogen) for 1 hour at room temperature. Primary antibodies were applied 
overnight at 4°C; primary antibodies were diluted in TBS I O.l%TX I 1% NGS I 1% 
FCS. Table 4.2 gives a summary of the primary antibodies and the dilutions used for 
immunocytochemical analysis of the cells. 
Table 4.2. A summary of the primary antibodies used and their cell type specificity. 
Antibody Company Raised in/clonality Dilution Cell type 
detected 
Pax7 DSHB Mouse/monoclonal 1/10 Transfected 
cells 
NeuN Abeam Mouse/monoclonal 11250 Neural 
GFAP Chemicon Rabbitlpolyclonal 11500 Astrocyte 
Nestin DSHB Mouse/monoclonal 1/100 Stem cell 
Beta III Tubulin Abeam Mouse/monoclonal 11500 Neural 
Ki-67 Abeam Rabbitlpolyclonal 11250 Proliferation 
Neurofilament Chemicon Rabbit/polyclonal 1/500 Neural 
OX42 Abeam Mouse/monoclonal 1/250 Dendritic 
macrophage 
Primary antibody was removed and the cells washed with TBS. Secondary 
antibody, anti mouse/rabbit (anti-IgG) linked to biotin (LSAB kit DAKO) was applied 
for one hour at room temperature, followed by the tertiary antibody, streptavidin 
linked to horse-radish peroxidise (HRP) (LSAB Kit DAKO), for one hour at room 
temperature. The tertiary antibody was removed; the cells were washed with TBS 
three times followed by TNS twice. Cells were visualised by a colour reaction using 
diaminobenzidine (DAB) (DAKO). The cells were finally washed with TNS, and 
cover-:-slipped using aqueous mounting medium to avoid losing stained cells. 
Primary antibodies used were: Pax7 (DSHB); neural markers Neurofilament 
(Chemicon), NeuN (Abeam) and Beta III tubulin (Abeam); the cell proliferative 
marker used was Ki67 (Chemicon); astrocyte marker was Glial fibrillary acidic 
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protein GFAP (Chemicon); the neural precursor marker Nestin (DSHB) and the 
macrophage I dendritic cell marker OX42 (Abeam), (see Table 4.2). The cells were 
visualised with an Olympus microscope and photographed using a Leica DC300 
camera. 
39 
CHAPTERS 
RESULTS 
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5.1 Cloning Pax.7 into the expression vector 
Pax7d previously cloned into the pcDNA3.1 DIV5 HIS-TOPO vector or vector 
alone were amplified in E. Coli. Purified vector DNA was run on a 1% agarose gel to 
check the DNA purity. The total size of the vector was 5514 bps and the Pax7 insert 
was 1560 bps, thus the expected size of the vector plus the insert was 7074 bps. 
Circular plasmids adopt multiple structural conformations, which in turn affect the 
rate at which they migrate in an agarose gel during electrophoresis. Thus three bands 
were visible on the gel, implying that three different structures were adopted by the 
circular pcDNA3.1 vector. 
11198bp 
7126bp 
5090bp 
4072bp 
3054bp 
Figure 5.1. Purified vector DNA containing Pax7 or 
vector alone control, were electrophoresed on 1% 
agarose gel adjacent to a 1 Kb ladder. The size of the 
purified product was approximately 7 kilo bases. 
Three bands are clearly visible, as expected for 
circular plasmids, which adopt different structural 
conformations in solution. -
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5.2 PCR to confirm Pax7 insertion into the vector 
PCR was performed on the purified plasmid DNA to confirm the Pax7 
insertion. Primers specific to the vector and insert, F4 and BGH, were used for the 
PCR. The expected PCR product size was 1748 bp. For the forward primer, only four 
base pairs are complementary to the vector and the rest of the primer spans the start of 
Pax7. The reverse primer was complementary to the vector; at a position a further 184 
base pairs from the end of the Pax7 insert. Thus the PCR product was 4bp plus 
1560bp plus 184bp which equals 17 48bp. 
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3054bp 
2036bp 
l636bp 
Figure 5.2. PCR was performed on purified vector 
DNA containing Pax7. The product size as 
expected was 1748 bp. There was no DNA 
detected in the blank (no DNA control) . 
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5.3 Confirmation o{Pax7 expression in transfected and selected cells 
Pl9 cells 
After cells were transfected and stably selected, the Pax7 insert was confirmed by 
immunocytochemistry. Untransfected P19 cells did not express any endogenous Pax7. 
As expected transfected cells express Pax7, confirming Pax7 expression from the 
vector. P19 cells transfected with vector alone did not survive gentamycin selection; 
all the P 19- vector cells died due to unsuccessful transfection. Therefore untransfected 
P 19 cells were used as a comparative control. 
" 
Figure 5.3 . A: untransfected P19 cells showing no expression of Pax7. B: P19 cells 
transfected with Pax7 detected by immunocytochemistry with Pax7 antibody. Every 
single transfected cell expressed Pax7. A representative sample of Pax7 transfected 
cells from clone one is shown here. Similar results were obtained for clone two. Scale 
bar lO)lm. 
The success of Pax7 transfection was crucial for the remaining experiments; 
without expression of Pax7 in the cells, the down stream target genes regulated by 
Pax7 would not be activated or would only be regulated at basal level. Thus we would 
not be able to assess Pax7 induced stem cell differentiation into specific neurons. 
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5.4 Gene expression in P 19 cells 
After RNA was extracted and converted to eDNA, PCR was performed to 
determine which genes were expressed by untransfected P 19 cells, termed basal gene 
expression. Stem cells are known to express low levels of a wide variety of genes. 
Thus they have wide potential for differentiation, and differentiation is often driven 
by micro-environmental factors surrounding the cells (Blondheim et al., 2006). When 
a cell starts to differentiate along a particular cell lineage, genes related to that cell 
type are up-regulated and the rest of the basal level gene expression is shut down. 
Here, testing for basal level gene expression patterns in untransfected P 19 cells 
indicated that a wide variety of genes were expressed in P19 cells at various 
expression levels (Refer to figure below). 
489 bp 
404 bp 
331 bp 
242 bp 
190 bp 
147 bp 
110 bp 
67 bp 
Figure 5.4. RT-PCR for P19 cells to detect basal level gene expression in 
untransfected cells. Variable band intensity on the gel for several genes indicated 
varied expression levels relative to GAP DH. Untransfected P19 cells did not express 
CDllB and expressed only very low levels of Pax7 and NCAM. Blank, no DNA 
control, for each set of primers was negative. 
44 
5.5 Gene expression in P19 + Pax7 trans(ected cells 
RT-PCR performed on RNA from Pl9 cells transfected with Pax7, indicated 
definitive suppression of GFAP and Nestin expression. When the intensity of bands 
was quantified, there was a significant difference in gene expression patterns 
compared to basal level gene expression levels present in P19 cells (Table 5.1). 
489 bp 
404 bp 
331 bp 
242 bp 
190 bp 
147 bp 
110 bp 
67 bp 
Figure 5.5. The gene expression patterns in P19 cells transfected with Pax7 differed 
from those in untransfected Pl9 cells. Expression of GFAP and nestin expression 
were significantly reduced in Pax7+ cells. The increased expression of Neurofilament 
and Beta III tubulin in Pax7+ cells indicates that Pl9+Pax7 cells have commenced 
differentiation along a neurogenic rather than an astrocytic lineage. Pax7 expression 
levels increased as did levels of Ephrin A2 and Engrailed 2 - all markers of dorsal 
midbrain neurons. 
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5.6 Gene expression in P19 + Pax7 transfected cells after 7 days in 
differentiation medium 
P19 and Pl9+Pax7 cells were grown in differentiation medium containing a-
MEM, F12, knockout serum and antibiotic without EGF and FGF (see section 4.8). 
The growth factors were withdrawn to ensure that the changes in gene expression 
observed after Pax7 transfection were not due to growth factors. Moreover the growth 
factors were used for rapid proliferation of cells, therefore to differentiate the 
transfected cells, growth factors were removed from the culture medium. 
The gene expression of P19 cells transfected with Pax7 did not change after 
seven days in medium without growth factors EGF and FGF. Only Pax7 expression 
was dramatically increased. Most other genes remained up or down regulated in 
patterns similar to that seen in transfected cells at day 0, but gene expression for most 
of the genes was slightly decreased when analysed by band intensity relative to 
GAPDH. 
489 bp 
404 bp 
331 bp 
242 bp 
190 bp 
147 bp 
110 bp 
67 bp 
Figure 5.6. RT-PCR for P19 cells transfected with Pax7 and grown in differentiation 
medium for 7 days. There was no great difference in gene expression relative to Pax7 
transfected cells at day 0. Most genes were in fact slightly down regulated when band 
intensity was analysed relative to GAPDH. 
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Table 5.1. Semi-quantitative analysis of gene expression levels in P19 and P19+Pax7 
transfected cells. Quantity One (Bio-Rad) was used to analyse band intensity relative 
to the GAPDH PCR product and used as a measure of fold difference in gene 
expression levels. 
P19 cells P19 Pax7 ( 0 days) P19 Pax7 ( 7 Days) Fold Difference 
Pax7 0.1 5 0.66 1.58 10 
Nestin 1.00 1.25 1.56 1.5 
Ephrin A2 0.37 2.54 1.44 6 
CD90 0.11 2.94 1.57 27 
CDllB Nil Nil 0.60 0.5 
CD44 0.65 1.82 1.50 3 
Neurofilarnent 0.30 2.79 1.55 9 
NCAM Nil 1.03 1.47 1.5 
Beta III tubulin 0.68 1.94 1.49 2.5 
Engrailed 2 0.86 2.85 0.54 3 
GFAP 0.60 0.52 0.16 0.25 
GAPDH 1.00 1.00 1.00 1 
In cells transfected with Pax 7, Pax7 expression increased at day 0 and was 
further increased after incubation in differentiation medium for 7 days. Neural genes 
were also up regulated, including nestin which is a neural progenitor marker. GFAP 
levels decreased after Pax7 transfection, whereas the mature neural markers Ephrin 
A2, Neurofilament, NCAM, Beta III tubulin and Engrailed increased in transfected 
cells relative to untransfected cells. The results indicate that the P19 stem cells are 
likely to differentiate into neurons after transfection with Pax7. 
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5. 7 Immunocytochemistry o(Pl9 cells and PJ9+Pax7 cells 
1. GFAP 
P19 P19 +Pax7 
Figure 5.7. Expression of GFAP in untransfected P19 cells and Pax7 transfected P19 
cells. Scale bar 10 ).!m. 
2. NeuN 
P19 P19 +Pax7 
. 
I 
Figure 5.8. Expression of the neuronal marker NeuN in untransfected P19 cells and 
Pax7 transfected P19 cells. Scale bar 1 Oj.!m. 
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Immunocytochemistry was performed to detect protein levels in the cells 
transfected with Pax7 relative to untransfected control cells. Pax? protein was clearly 
evident in transfected cells while no Pax? was detected in untransfected cells (Figure 
5.3). Furthermore both transfected and untransfected cells expressed GFAP, an 
astrocyte marker (Figure 5.7), however the levels of GFAP in each cell may differ as 
indicated by RT-PCR. The levels of GFAP protein in Pax7 transfected cells appears 
lower relative to untransfected P19 cells, however this was not quantified. 
Expression of NeuN, a marker for mature neurons, is evident m Pax7 
transfected cells but was not present in the untransfected cells (Figure 5.8). 
Expression ofNeuN is an indication that the cells have exited from the cell cycle and 
maturation and differentiation towards a neuron has commenced (Samat et al., 1998). 
All the transfected cells expressed NeuN and therefore were on a path of neuronal 
differentiation as suggested by protein expression. 
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3. Nestin 
P19 
II 
Figure 5.9. Expression of neural precursor marker Nestin in untransfected P19 cells 
and Pax7 transfected P19 cells. Scale bar 1 O~m. 
4. Beta III Tubulin 
P19 P19 +Pax7 
I 
.. 
Figure 5.10. Expression of Beta III tubulin m untransfected P19 cells and Pax7 
transfected P19 cells. Scale bar lO~m. 
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N estin expresswn appeared reduced in transfected cells compared to 
untransfected control cells. P19 stem cells showed expression of nestin at a basal 
level, but as the cell differentiated towards a neural lineage, nestin expression 
appeared diminished (Figure 5.9). Nestin is an intermediate filament protein 
expressed predominantly by neural stem cells and its thought to be an important 
marker of early neural cells (Wislet-Gendebien et al., 2003). When a cell is fully 
differentiated and matured, nestin is not expressed at all. 
Beta III tubulin is a cellular structural protein expressed as five isoforms. Beta 
III tubulin is specifically expressed as a structural protein exclusively in neurons (Lee 
et al., 1990). Levels of Beta III tubulin in the Pax7 transfected cells increased, 
indicating that the transfected cells were differentiating towards a neural lineage 
(Figure 5.1 0). Not all untransfected cells expressed Beta III tubulin whereas, by 
contrast, all transfected cells expressed high levels of Beta III tubulin. 
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5. Ki67 
Figure 5.11. Expression of proliferative marker Ki67 in untransfected P19 cells and 
Pax7 transfected P19 cells. Scale bar 10~-tm. 
6. Neuro(ilament 
Figure 5.12. Expression of neuronal marker Neurofilament in untransfected P19 cells 
and Pax7 transfected P19 cells. Scale bar 1 0~-tm. 
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7. OX42 
P19 
' '·'' 
~ 
t. (' 
Figure 5.13. Expression of dendretic marker OX-42 in untransfected P19 cells and 
Pa.x7 transfected P19 cells. Scale bar lOj.tm. 
Ki67 is a protein that is expressed in the nuclei of proliferating cells. Absent 
only in resting cells, cells in the G 1, S, G2, and M phase of the cell cycle express this 
marker (Keng and Siemann, 1998). Both Pax7 transfected and untransfected cells 
expressed nuclear Ki67 (Figure 5.11 ), indicating that the cells remained proliferative 
after Pax7 transfection. 
Neurofilament is a structural protein present in neurons, and is expressed by 
both early neuroblasts as well as post mitotic neurons. It is indicative of cell 
differentiation towards a neural lineage. Neurofilament is a filament protein 
consisting of three forms: light, medium and heavy neurofilament, all of which are 
structural proteins found in the cytoplasm of neurons. In Pax7 transfected cells 
neurofilament was observed in the cell body and projecting cell processes (Figure 
5. 12). In untransfected cells, the expression of neurofilament was restricted to the 
region around the nucleus, denoting undifferentiated cells. 
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OX-42 is a marker of dendritic macrophages. Both transfected and 
untransfected cells did not express any OX-42 (Figure 5.13). 
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5.8 Immunocytochemistry o{NIH3T3 cells and Pax7+ NIH3T3 cells 
Immunocytochemistry was also performed on NIH3 T3 cells and on NIH3 T3 
cells transfected with Pax7 to determine expression of Pax7 and selected genes. The 
cells were transfected with Pax7d, and stable clones were selected and analysed for 
Pax7 expression as described previously in section 4.6. Vector transfection was 
performed but NIH3 T3 cells with vector alone did not survive gentamycin selection. 
Untransfected NIH3T3 cells were used as comparative controls. 
1 Pax7 
NIH3T3 NIH3T3 + Pax7 
' .. 
•'' .,
1 
J 
' .... 
.. ~· 
Figure 5.14. Expression of Pax7 in NIH3T3 untransfected cells compared to Pax7 
transfected NIH3T3 cells. Scale bar 1 OJ.!m. 
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2 GFAP 
NIH3T3 NIH3T3 + Pax7 ~~~----------------------~ 
'J 
Figure 5.15. Expression of GFAP in NIH3T3 untransfected cells compared to Pax7 
transfected NIH3T3 cells. Scale bar lOJJ.m. 
3 NeuN 
NIH3T3 
Figure 5.16. Expression ofNeuN in NIH3T3 untransfected cells compared to Pax7 
transfected NIH3T3 cells. Scale bar lOJJ.m. 
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4 Nestin 
Figure 5.17. Expression of Nestin in NIH3T3 untransfected cells compared to Pax7 
transfected NIH3T3 cells. Scale bar lOJ..Lm. 
5 Beta III tubulin 
NIH3T3 NIH3T3 + Pax7 
I 
Figure 5.18. Expression of beta III tubulin in NIH3T3 untransfected cells compared to 
Pax7 transfected NIH3T3 cells. Scale bar lOJ..Lm. 
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6 Ki67 
NIH3T3 NIH3T3 + Pax7 
Figure 5.19. Expression of Ki67 in NIH3T3 untransfected cells compared to Pax7 
transfected NIH3T3 cells. Scale bar lOJ.!m. 
7 Neurofilament 
NIH3T3 NIH3T3 + Pax7 
I 
Figure 5.20. Expression ofNeurofilament in NIH3T3 untransfected cells compared to 
Pax7 transfected NIH3T3 cells. Scale bar lOJ.!m. 
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8 OX-42 
NIH3T3 NIH3T3 + Pax7 
1 
Figure 5.21. Expression of OX-42 in NIH3T3 untransfected cells compared to Pax7 
transfected NIH3T3 cells. Scale bar 1 o~-~.m. 
There was no difference between gene expression patterns of NIH3 T3 cells 
and Pl9 cells. Both untransfected cell lines were negative for Pax7 while transfected 
cell lines were positive for Pax7; Pax7 protein was present in 80% - 100% of the 
cells. Expression of neural markers neurofilament, Nestin, NeuN and Beta III tubulin 
increased in NIH3T3 cells after transfection with Pax7 as observed in P19 transfected 
cells. In NIH3 T3 transfected cells Ki67 expression appeared increased relative to 
untransfected cells. OX-42 was negative in both transfected and untransfected 
NIH3T3 cells. Since immunocytochemistry results were consistent with those 
obtained from Pl9 cells transfected with Pax7, RT-PCR was not performed on 
NIH3T3 cells. 
59 
Similar results in P 19 and NIH3 T3 cells confirmed that previous experiments 
(Ziman et al., 2001) in which it was observed that Pax7 induced differentiation ofP19 
cells along a neurogenic lineage, were not due to artefacts or an innate property of the 
cell line. 
5.9 Immunocytochemistry (or rBMSSCs 
Immunocytochemistry was performed on rBMSSCs to assess Pax7 and neural 
gene expression in untransfected cells. The transfected cells survived two weeks after 
transfection but died during selection, therefore no RT-PCR or immunocytochemistry 
could be performed on the Pax7 transfected cells. 
• 
• 
A.Pax7 B. NeuN 
Figure 5.22. Expression of (A) Pax7 and (B) NeuN in untransfected BMSSCs. No 
Pax7 expression was evident whereas NeuN expression was clearly present in the 
nucleus. Scale bar 1 0!-!m. 
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A.GFAP B. Nestin 
C. Beta Ill tubulin I I D. Ki67 I 
Figure 5.23. Expression of (A) GFAP, (B) Nestin, (C) Beta III tubulin and (D) Ki67. 
GF AP was present around the nucleus, with little staining in the cytoplasm. Nestin 
was present in the cytoplasm and around the nucleus. Beta III tubulin was present 
throughout the cell. Proliferative marker Ki67 was specifically restricted to the 
nucleus. Scale bar 1 Oj.im. 
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A. N eurofilament B. OX-42 
Figure 5.24. Expression of (A) neuronal marker Neurofilament and (B) dendritic 
marker OX-42 in untransfected BMSSCs. Neurofilament is highly expressed and 
present only in the cytoplasm. OX-42 was not expressed. Scale bar lOj.tm. 
Rat BMSSCs do not express Pax7 (Figure 5.22 A). NeuN was found 
expressed in the nucleus of BMSSCs but not in the cytoplasm as expected (Figure 
5.22 B). The nuclear expression of NeuN in these stem cells was a surprise. NeuN 
expression was confmed to very dark staining regions in the nucleus, possibly at a site 
of active chromatin, indicative of basal level expression of NeuN. NeuN is usually 
only expressed when a cell exits from neural progenitor cell status and becomes a 
fully differentiated neuron (Samat et al. , 1998). 
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GF AP was expressed particularly in the cytoplasm but not in the nucleus of 
untransfected BMSSC cells (Figure 5.23 A). The staining was evenly spread within 
the cytoplasm. 
Nestin expression in untransfected cells was in the cytoplasm and specifically 
around the nucleus but not in the nucleus (Figure 5.23 B), as expected for a stem cell 
line. 
Beta III tubulin was expressed evenly throughout the cell at low levels (Figure 
5.23 C). Ki67 expression in untransfected cells was specific to the nucleus, with dark 
chromatin staining visible (Figure 5.23 D), indicating proliferating cells. 
Expression of Neurofilament in untransfected cells was specific to the 
cytoplasm. There was no cell body staining and the cytoplasmic staining was evenly 
distributed through out the cytoplasm (Figure 5.24 A). By contrast OX-42 expression 
was not detected in untransfected cells at all (Figure 5.24 B). 
Thus BMSSCs express neural genes at low levels, thus indicating the potential of 
BMSSCs to differentiate along a neurogenic lineage. 
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CHAPTER6 
DISCUSSION 
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6.1 Justification (or the use o{Pax7d 
In this study, the transcription factor Pax7 was used to induce the 
differentiation of stem cells into a homogenous population of neurons. As a 
transcription factor, Pax7 regulates the expression of downstream target genes that 
determine cell lineage and differentiation. In vivo Pax7 has been implicated in cell 
specification of midbrain neurons during embryonic development (Basch et al., 2006). 
Given the importance of Pax7 in CNS development we anticipated that by 
transfecting undifferentiated cells with Pax7, the cells will be directed along a 
neurogenic lineage. 
The Pax7 gene encodes several transcripts and each encoded isoform is 
believed to have a specific set of target genes, however this remains to be determined 
(White and Ziman, 2006). In this project the Pax7d transcript (Appendix 2) was used 
in transfections of both P 19 and NIH3 T3 cells. 
Although no specific transcript of Pax7 has been assigned an individually 
distinct function, in vitro experiments suggest that Pax7d may be important in neural 
differentiation. It has been demonstrated that the transcripts Pax7b and Pax7d are 
specifically expressed in the brain of adult mice (Ziman et al., 1997). Moreover when 
P19 cells were transfected with Pax7d the cells were induced to differentiate along a 
neurogenic lineage (Ziman et al., 2001). It is possible that the Pax7d transcript 
functions to regulate neural genes in the tectum to specify tectal neural fate (Thomas 
et al., 2004; Ziman et al., 2001). 
Previously, transfection of P19 cells with either Pax7 or Pax6 resulted in 
neural differentiation of the cells. While it was determined that it was the expression 
of Pax genes that induced the neural differentiation of the cells, it was thought that 
possibly the default pathway of P 19 cells may be neural. Therefore we assessed the 
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neural differentiation of several cell lines following transfection with Pax7. Our 
results showed that both gene and protein expression patterns were similar in all the 
cell lines assessed. Thus ectopic expression of Pax7 has the ability to induce neural 
differentiation in multiple progenitor cell lines. 
Expression of Pax7 in multiple transfected cells induced upregulation of 
neural genes, indicating that upregulation of neural genes was due to Pax7. Stem cells 
were transfected with Pax7 to assess the ability of this gene to induced neural 
differentiation for future transplant therapies. Experiments were conducted in P 19 
cells, NIH3T3 cells and BMSSCs to compare neural induction in all three cell lines. 
Sadly, while the transfection of BMSSCs was successful, the cells did not survive 
selection and no further results could be obtained. Future studies will concentrate on 
perfecting cell culture and transfection of these cells for future stem cell therapies 
6.2 Novel findings 
When P19 stem cells were transfected with the gene Pax7, the expression 
levels of several genes were altered. The differences in the gene expression and 
protein levels were due to the presence of Pax7, since the control cells had little or no 
Pax7 expression. It was clear from our results that neural differentiation genes were 
upregulated while glial specific genes were down regulated by Pax7. 
Neurofilament is a structural protein present in neurons and also serves as a 
marker for neural differentiation; increased expression is an indication that the cells 
are moving towards neural differentiation. Neurofilament was upregulated in the 
presence of Pax7 in transfected cells relative to untransfected cells. Stem cells would 
have little or no neurofilament expression, when assessed by immunocytochemistry 
and only low levels of neurofilament (basal level expression) were detected by R T-
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PCR in untransfected cells. Both cell lines expressed neurofilament at a higher level 
after transfection with Pax7, indicating some differentiation towards a neuronal 
lineage. 
Further support for this was the upregulation of NCAM in transfected cells. 
Neural cell adhesion molecule is a marker of mature migrating neurons. NCAM plays 
a vital role in neural cell proliferation and migration during development. It has 
important implications in synapse formation between neurons and the establishment 
of new connections through cell-cell adhesion. Spatial and temporal expression plays 
a pivotal role in neurogenesis during development (Ronn et al., 2000). A long chain of 
sialic acid is added to NCAM to form polysialic acid NCAM which is negatively 
charged (Kiss and Rougon, 1997). Neural migration is facilitated by the negative 
charge due to attachment ofpolysialic acid on NCAM which is a membrane spanning 
protein expressed on the neurons to help axonal growth and neural migration. 
Attachment of polysialic acid on NCAM prevents any synapse formation and 
promotes neural migration. NCAM is therefore an important cell membrane protein 
expressed by neurons, in which conjunction with polysialic acid aids neural migration 
and synaptogenesis. Our findings indicate NCAM was not expressed at all in the 
control untransfected cells but was expressed in transfected cells. NCAM expression 
in transfected cells suggested neural differentiation had been induced by the presence 
ofPax7. 
Further experiments are required to determine" whether increased Pax7 
expression in transfected cells, causes increased cell migration due to increased 
polysialic acid NCAM expression. 
Beta III tubulin is also a structural protein found in neurons. Although tubulin 
is expressed widely in a variety of cells, the beta three isoform is particularly 
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expressed in neurons. In our experiments conducted here, as found previously 
(Blondheim et al., 2006) expression levels in untransfected cells were low. With 
introduction of Pax7, Beta III tubulin expression was increased. 
Beta III tubulin forms the cytoskeleton structure of the neuron. Studies have 
shown that increased expression of Beta III tubulin in neural precursor cells indicates 
the formation of neuronal axons (Moskowitz and Oblinger, 1995). Our results are 
consistent with the finding by Lee and Pixley; who showed that Beta III tubulin is 
particularly expressed in high levels within the somata of new born neurons but shows 
little expression in mature neurons (Lee et al., 1990). Thus Beta III tubulin is 
implicated in building up of the cytoskeletal structure of differentiating stem cells 
towards a neural precursor lineage. Upregulation of Beta III tubulin in Pax7+ stem 
cells may indicate that Pax7 is a suitable transcription factor for use in differentiation 
of stem cells for transplant therapies. Untransfected BMSSCs however also expressed 
Beta III tubulin. Blondheim (Blondheim et al., 2006) who showed similar Beta III 
tubulin expression in untransfected BMSSCs and hypothesised that expression of low 
levels of neural markers in stem cells indicated their ability to differentiate along a 
neurogenic lineage. 
Stronger evidence that Pax7 induces neurogenic differentiation in stem cells is 
provided by the finding that NeuN was upregulated in transfected cells. NeuN is a 
nuclear protein antigen that is used to identify post mitotic neuron (Weyer and 
Schilling, 2003). It is used as a marker for neuronal matura~ion in the nervous system 
and is predominantly localised to the cell nucleus. Both P19 and NIH3T3 transfected 
cells expressed similar patterns of NeuN, indicating that Pax? upregulated NeuN and 
induced neural differentiation. NeuN has specific staining patterns; it is preferentially 
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found in areas of low chromatin density and virtually excluded from densely packed 
DNA (Lind et al., 2005). 
GF AP has been used as a biomarker for neuroglial cells, as it is a protein 
usually expressed by astrocytes (Hausmann et al., 2000; Maubach et al., 2006). Of 
particular note was our ftnding that the expression level of GF AP was dramatically 
altered in the presence of the Pax7 protein when assessed by R T-PCR. Thus, 
introducing Pax7 represses the expression of GF AP which possibly indicates 
repression of an astrocytic lineage (Lee et al., 2006), in transfected differentiating 
cells. 
The protein level of GF AP appeared unchanged after Pax7 transfection, in 
both P19 and NIH3T3 cells, which could be an indication that the turnover rate of 
GF AP is slow. The continuing protein expression of GF AP may be an indication that 
ubiquitin mediated protein degradation is active at very low levels for GF AP protein. 
Other studies have shown that different cellular proteins have variable turnover rates 
through ubiquitin mediated protein degradation (Ciechanover, 1991). 
The upregulation of Nestin mRNA by Pax7 transfection in P19 cells was an 
unexpected result. Nestin is an intermediate ftlament protein that has typically been 
associated with neuroepithelial cells and is an indicator of cells at an early stage of 
neural differentiation (Dahlstrand et al., 1995). During the development of CNS, 
proliferating neuroepithelial cells express Nestin (Lendahl et al., 1990). However, 
nestin is no longer considered to be exclusive to neural stem cells but rather is an 
indication of a multi potent progenitor cell, as it has also been shown to be expressed 
in muscle progenitor cells and some epithelial cells (Mokry and Nemecek, 1998). 
Since nestin expression in stem cells bridges the gap between neural progenitor stem 
cells and differentiated neurons, Pax7 transfected cells expressing Nestin could be 
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said to be on a path towards neural differentiation. BMSSCs also expressed nestin, 
which indicates the potential of BMSSCs to differentiate along a neural lineage. Other 
studies have shown similar expression of Nestin in BMSSCs (Scintu et al., 2006; 
Tondreau et al., 2004). 
The continued expression of Nestin in Pax? transfected cells suggested that 
even though the cells expressed NeuN and other markers of mature neurons, the cells 
were still at an early stage of neural differentiation. Alternatively, Nestin expression 
after transfection could be an artefact of culture conditions. This is supported by a 
study that showed that the passage number and presence of serum in culture were two 
factors that affect expression of nestin (Wislet-Gendebien et al., 2003). Further work 
needs to be done to elucidate the reasons for the continued expression of nestin in 
Pax7 transfected cells. 
Markers of specific dorsal midbrain neurons were consistently increased in 
Pax7 transfected cells. Ephrin A2 (Ephrin Alpha receptor 2) is a marker of mature 
differentiated neurons in the dorsal midbrain or tectum. Class A Ephrins are protein 
coupled receptors that are linked to the cell membrane by a GPI anchor. Ephrin 
molecules play a vital role as regulators of developmental processes such as axon 
guidance, cell migration and synapse formation (Wilkinson, 2001; Holmberg et al., 
2005). These molecules provide a feedback system for cells at different stages of 
maturation and connectivity, and regulate the number of cells generated in the brain. 
Upregulation of Ephrin A2 in Pax7 transfected cells bot~ P19 and NIH3T3 cells, 
provided further evidence that transfected cells were undergoing neuronal 
differentiation. While Ephrin A2 might not be directly bound by the Pax? 
transcription factor, it is certain that its expression is regulated by Pax?. This is 
supported by previous studies, which showed that Pax? regulated expression of 
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Ephrin A2 in vitro (Thomas et al., 2004) and in vivo (Thompson et al, 2006). Pax7 
and ephrin A2 may regulate polarity and topography of the dorsal midbrain. Our 
findings here lend further support to these previous studies and indicated that 
transfection of stem cells with Pax7 produced a specific midbrain neural progenitor 
cell, useful for future stem cell transplant therapies. 
Engrailed is also a transcription factor that determines the structure and 
polarity of the dorsal midbrain (Itasaki et al., 1991). Expression of Engrailed was 
dramatically increased in transfected cells. Up regulation of Engrailed due to the 
presence of Pax7 provided further evidence that Pax7 induced differentiation of stem 
cells towards a neural lineage specific to the midbrain. 
So far we have shown by RT-PCR and immunocytochemistry that Pax7 
upregulated key neuronal genes Neurofilament, Engrailed, NCAM, Beta III tubulin 
and down regulated astrocytic gene GF AP. The expression profile of these genes 
indicated that the transfected cells had differentiated into early stages neurons and not 
astrocytes. Increased expression of Ephrin A2 which is a marker for tectal neurons 
and NeuN, a mature neuron marker as well as Engrailed provided further evidence 
that the differentiated cells were neurons specific to the tectum. Thus Pax7 induced 
neurons may ultimately be used as cellular material for transplant therapies in the 
tectum. 
It is clear from our results that while Pax7 transfected cells expressed 
markers of differentiated neurons, they also expressed stem cell markers such as CD 
90, CD44 and CD11B. Transfected cells also expressed Ki67, which is a marker of 
proliferation. NIH3T3 cells in particular expressed Ki67 after transfection with Pax7, 
when growth factors were withdrawn, the expression of proliferation markers 
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decreased. Growth factors are known to cause rapid proliferation in stem cells (Villa 
et al., 2000). Thus it was clear that transfected cells did not fully differentiate. 
It is also now clear that production of a homogeneous population of neurons 
is not possible with the use of just one transcription factor. While the cells transfected 
with Pax7 showed several characteristic of midbrain neurons, they still retained stem 
cell features. This may be an artefact of the stem cell lines used as they are engineered 
to remain proliferative. Alternatively, differentiation even in vivo may proceed via 
several steps in which markers of both differentiated and undifferentiated cells are 
present. 
BMSSCs are suitable cellular material for transplant therapies, but they are 
difficult to culture. The cells proliferated slowly and when transfected remained 
firmly attached to the plastic, and thus were not transferable into 
immunocytochemistry wells. BMSSCs are also affected by small variations in culture 
conditions i.e. different serum batches affect growth conditions. Future research will 
need to take these factors into consideration to ensure optimal culture conditions of 
BMSSCs neural induction. 
In summary, in Pax7 transfected cells, neural genes were upregulated and 
cells differentiated towards a neural lineage. The key genes upregulated by 
transfection of Pax7 were Neurofilament, Beta III tubulin, Engrailed 2, Ephrin A2, 
NCAM and NeuN. The cell types produced in two transfected cell lines were similar 
strengthening the case for the use of developmental transcription factor to produce 
specific neurons in culture. 
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6.3 Future directions 
Further work is needed to characterise and carefully quantify which genes 
are expressed at a basal level in stem cells. Micro-array is a useful tool to assess gene 
expression at a basal level. The transfected cells also need further characterisation 
before use in cell replacement therapy. Transfection into freshly isolated BMSSCs 
may produce more consistent results. 
Additional work is also needed to identify the ability of individual Pax7 
transcripts to regulate key genes associated with neural cell differentiation. Here, we 
only transfected one transcript, Pax7d; two or more transcripts may have yielded 
better results. 
Research is currently underway to assess the key genes that are regulated by 
the transcription factor Pax7 in vivo. This information may be useful in assessing the 
molecular mechanisms responsible for cell differentiation towards one lineage and not 
another. 
Developmental genes are still thought to provide the best possible 
mechanism of producing differentiated neurons in vitro for use in stem cell transplant 
therapies. Our results provide further support for this theory. 
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APPENDIX! 
Vector sequence ofpcDNA3.1DN5-His-TOPO vector (Invitrogen) 
GACGGATCGGGAGATCTCCCGATCCCCTATGGTCGACTCTCAGTACAATCTGCTCTGATGC 
CGCATAGTTAAGCCAGTATCTGCTCCCTGCTTGTGTGTTGGAGGTCGCTGAGTAGTGCGCG 
AGCAAAATTTAAGCTACAACAAGGCAAGGCTTGACCGACAATTGCATGAAGAATCTGCTT 
AGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGGCCAGATATACGCGTTGACATTGAT 
TATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGA 
GTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGC 
CCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGAC 
GTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATAT 
GCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCA 
GTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATT 
ACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGG 
GGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAAC 
GGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTG 
TACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCCACTGCTTACT 
GGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGGCTAGTTAAGCTTGG 
TACCGAGCTCGGATCCAGTACCCTTCAC GGGTCAAGACAATTCTGC 
AGATATCCAGCACAGTGGCGGCCGCTCGAGTCTAGAGGGCCCGCGGTTCGAAGGTAAGCC 
TATCCCTAACCCTCTCCTCGGTCTCGATTCTACGCGTACCGGTCATCATCACCATCACCATT 
GAGTTTAAACCCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTG 
CCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAA 
ATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGG 
GGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTG 
GGCTCTATGGCTTCTGAGGCGGAAAGAACCAGCTGGGGCTCTAGGGGGTATCCCCACGCG 
CCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACA 
CTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGC 
CGGCTTTCCCCGTCAAGCTCTAAATCGGGGCATCCCTTTAGGGTTCCGATTTAGTGCTTTA 
CGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCC 
TGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTT 
CCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTG 
GGGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTAA 
TTCTGTGGAATGTGTGTCAGTTAGGGTGTGGAAAGTCCCCAGGCTCCCCAGGCAGGCAGA 
AGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCAGGTGTGGAAAGTCCCCAGGCTCC 
CCAGCAGGCAGAAGTATGCAAAGCATGCATCTCAATTAGTCAGCAACCATAGTCCCGCCC 
CTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCT 
GACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCTGCCTCTGAGCTATTCCAGAA 
GTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTCCCGGGAGCTTGTATA 
TCCATTTTCGGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGAT 
GGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCA 
CAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCG 
GTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCG 
CGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGTCACTG 
AAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCTGTCATCTC 
ACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCT 
TGATCCGGCTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTAC 
TCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGC 
GCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGTCGT 
GACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGATTC 
ATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGT 
GATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCG 
CCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGCGGG 
ACTCTGGGGTTCGCGAAATGACCGACCAAGCGACGCCCAACCTGCCATCACGAGATTTCG 
ATTCCACCGCCGCCTTCTATGAAAGGTTGGGCTTCGGAATCGTTTTCCGGGACGCCGGCTG 
GATGATCCTCCAGCGCGGGGATCTCATGCTGGAGTTCTTCGCCCACCCCAACTTGTTTATT 
GCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTT 
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TTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGTAT 
ACCGTCGACCTCTAGCTAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAAT 
TGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGG 
GGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCAGT 
CGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTT 
TGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTG 
CGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGAT 
AACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGG 
CCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACG 
CTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGG 
AAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTC 
TCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTATCTCAGTTCGGTGTA 
GGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCC 
TTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAG 
CAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGA 
AGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGA 
AGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTG 
GTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAG 
AAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGG 
GATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGA 
AGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAA 
TCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCC 
GTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATA 
CCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGG 
GCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCC 
GGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTAC 
AGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGA 
TCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTC 
CGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCA 
TAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCA 
AGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGG 
ATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGG 
GGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGC 
ACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGA 
AGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACT 
CTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATAT 
TTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGC 
CACCTGACGTC 
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APPENDIX2 
The eDNA sequence of Pax7d transcript which was cloned into the vector with 
altered nucleotide sequence. 
ATGGCGGCGCTGCCCGGCGCGGTCCCCAGGATGATGAGACCCGGCCCGGGGCAGAACTACCCGCGCACC 
~AGIGTGGCGACTCCGGATGTGGAG 
AAAAAGATTGAGGAGTATAAGAGAGAGAACCCCGGGATGTTCAGCTGGGAAATCCGGGACCGGCTGCTG 
AAGGACGGTCACTGCGACCGAAGCACGGTGCCCTCAGpTTTAGif 
'•.••GGAACCGTCTGGATGAGGGCTCAGATGTGGAATCA 
GAACCCGACCTCCCCCTGAAGCGCAAGCAGCGCCGCAGTCGGACCACGTTCACAGCCGAGCAGCTGGAG 
GAGCTGGAGAAGGCCTTCGAGAGGACCCACTACCCGGACATCTACACCCGGGAGGAGCTGGCACAGAGG 
• ATGGAGGCAGCACA 
GTACACAGGCCCCAGCCCCTTCCGCCATCAACCATGCATCAGGGTGGGCTGGCTGCGGCCGCTGCAGCA 
GCGGACACCAGCTCTGCCTACGGAGCCCGCCACAGCTTCTCCAGCTACTCTGACAGCTTCATGAACCCT 
GGGGCTCCCTCCAACCACATGAACCCTGTCAGCAATGGCCTGTCTCCTCAG .. 
. /·1\CTGCTGTTGATTACCTGGCCAAAAACGTGAGCCTGTCCACACAGCGC 
CGTATGAAGCTTGGGGAACACTCCGCTGTGCTGGGACTTCTTCCTGTGGAAACGGGACAAGCCTACTAG 
Notes: jCAGI is included in the transcript Pax7d while IGTTTAGI is excluded from 
Pax7. 
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APPENDIX3 
Buffers and solutions 
1. lOx Phosphate Buffered Saline (lOx PBS) 
Sodium chloride NaC1 .................................................. 85g 
- Di-hydrogen sodium phosphate .................................. .4g 
- Di-sodium hydrogen phosphate .................................. .10.6g 
- ddH20 ............................................................................ 1 L 
- pH7.4 with cHCl 
2. lOx Tris Buffered Saline (lOx TBS) 
- TRIS base ...................................................................... 48g 
- Sodium chloride .......................................................... .36g 
- ddH20 ............................................................................ 1L 
- pH7 .4 with cHCl 
3. lOx Tris Non-Saline (lOx TNS) 
- TRIS base ...................................................................... 60g 
- ddHzO ............................................................................ lL 
- pH7 .4 with cHCl 
4. 4% Paraformaldehyde (4% PFA) 
- Paraformaldehyde ......................................................... 40g 
- Heat to dissolve PF A 
- pH7 .4 with orthophosphoric acid 
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